6ŒŽ30“ú�i“y�j |
 |
Opening Remarks |
|
|
|
|
“¡àV�@—²•v |
2007”N“xŒ¤‹†‰ï ‰ï’·�^
�i“Æ�j�‘—§•a‰@‹@�\ŽO�d•a‰@ —Õ�°Œ¤‹†•” |
|
|
|
|
|
 |
Session 1 |
|
�À�@’· |
ŽRŒû�@�³—Y |
“Œ‹ž‘åŠwˆãŠw•”•�‘®•a‰@ ƒAƒŒƒ‹ƒM�[ƒŠƒEƒ}ƒ`“à‰È |
|
|
|
1-1 |
ŽÀŒ±“Iƒ}ƒEƒX�S‹Ø‰Š‚̉Š�Ç�×–E�Z��‚É‚¨‚¯‚éJanus kinase�iJAK�j‚Ì–ðŠ„ |
|
|
|
•½àV�@�«’j |
‘å�ãˆã‰È‘åŠw ‘æ3“à‰È |
|
|
|
1-2 |
OAŠ´�샂ƒ‹ƒ‚ƒbƒg‚Ì‹CŠÇ‚É‚¨‚¯‚éƒoƒjƒ�ƒCƒhŽó—e‘̂ɂ‚¢‚Ä |
|
|
|
“nç³�@’¼�l |
�¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw ŒÄ‹zŠí�EŠ´�õ�Ç“à‰È |
|
|
|
1-3 |
šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éConserved noncoding sequence 1�iCNS-1�j‚̉ð�Í |
|
|
|
Š�ŽR —Yˆê˜Y |
�i“Æ�j�‘—§•a‰@‹@�\ ‘Š–ÍŒ´•a‰@ —Õ�°Œ¤‹†ƒZƒ“ƒ^�[ |
|
|
|
|
|
|
|
 |
Session 2 |
|
�À�@’· |
‰Á“¡�@�•F |
ŒQ”nŒ§‰q�¶ŠÂ‹«Œ¤‹†�Š |
|
|
|
2-1 |
ƒqƒg––�½ŒŒT�×–E‚É‚¨‚¯‚éTh1/Th2•ª‰»‚Ì•sŠ®‘S�«‚Æ‚»‚Ì—vˆö |
|
|
|
�_�À�@�@�C |
“Œ‹ž“s—Õ�°ˆãŠw‘��‡Œ¤‹†�Š ‰Ô•²�ǃvƒ�ƒWƒFƒNƒg |
|
|
|
2-2 |
ƒqƒXƒgƒ“’EƒAƒZƒ`ƒ‹‰»�y‘f‘jŠQ–ò‚É‚æ‚é FIP1L1-PDGFRƒ¿Œ¸�‹@�˜‚̉ð�Í |
|
|
|
�ÎŒ´�@Œ¤Ž¡ |
“Œ–k‘åŠw ‘åŠw‰@–òŠwŒ¤‹†‰È ‹@”\•ªŽq�¶‰»Šw•ª–ì |
|
|
|
2-3 |
‹CŠÇŽxšb‘§‚É‚¨‚¯‚é�DŽ_‹…‹@”\‚ɑ΂·‚éHGF‚ÌŒø‰Ê |
|
|
|
ˆÉ“¡�@�@˜j |
�H“c‘åŠw ˆãŠw•” —Õ�°ŒŸ�¸ˆãŠw |
|
|
|
|
|
|
|
|
|
|
 |
Session 3 |
|
�À�@’· |
‘å‹v•Û Šì—Y |
ˆã—Ö@�l�m—Y‰ï •ä�‚•a‰@ |
|
|
|
3-1 |
ŒŒŠÇ“à”ç�×–E‚Ì�DŽ_‹…�Ú’…—U“±”\‚É‚¨‚æ‚Ú‚·IFN-ƒ¿/ƒÀ‚Ì�ì—p |
|
|
|
�¬—Ñ�@ˆÐ�m |
�é‹Êˆã‰È‘åŠw ŒÄ‹zŠí“à‰È |
|
|
|
|
|
|
|
|
3-2 |
Budesonide/formoterol‚ÍŠˆ�«‰»�DŽ_‹…‚Ì�Ú’…”\‚ð�C�ü‚µ‚È‚¢‚ª�AŠˆ�«‰»—U“±Œã’PŠj‹…‚ÌIL-5�ARANTES�ATNF-ƒ¿ŽY�¶‚ð—}�§‚·‚é |
|
|
|
ž[�@�@’m�s |
�é‹Êˆã‰È‘åŠw‘��‡ˆã—ÃZƒ“ƒ^�[ ŒÄ‹zŠí“à‰È |
|
|
|
3-3 |
ƒAƒŒƒ‹ƒM�[�«‰Š�ǂɂ¨‚¯‚éPPARƒÁ‚Ì�DŽ_‹…�Ú’…”\�§Œä |
|
|
|
�ç—t�@‹M�l |
�H“c‘åŠw ˆãŠw•” —Õ�°ŒŸ�¸ˆãŠw |
|
|
|
|
|
|
|
|
|
|
|
|
 |
Session 4 |
|
�À�@’· |
‰i“c�@�@�^ |
�é‹Êˆã‰È‘åŠwˆãŠw•” ŒÄ‹zŠí“à‰È |
|
|
|
4-1 |
�D’†‹…—R—ˆƒvƒ�ƒeƒA�[ƒ[‚É‚æ‚é�DŽ_‹…‚ÌŠˆ�«‰» |
|
|
|
–ìŠÔ�@�áŽq |
�i“Æ�j�‘—§•a‰@‹@�\ŽO�d•a‰@ —Õ�°Œ¤‹†•” |
|
|
|
4-2 |
�DŽ_‹…‹@”\‚É‚¨‚¯‚éƒzƒXƒzƒŠƒp�[ƒ[C‚Ì–ðŠ„ |
|
|
|
�²–ì ˆÀŠóŽq |
‹ß‹E‘åŠw ˆãŠw•” ŒÄ‹zŠí�EƒAƒŒƒ‹ƒM�[“à‰È |
|
|
|
4-3 |
Interferon-ƒÁ‚ÍTh2ƒTƒCƒgƒJƒCƒ“‚É‚æ‚é�DŽ_‹…‚Ì�×–E“àƒVƒOƒiƒ‹•ªŽq‚ÌƒŠƒ“Ž_‰»‚ð˜´�i‚·‚é |
|
|
|
ŽRŒû�@‹MŽj |
ŒQ”nŒ§‰q�¶ŠÂ‹«Œ¤‹†�Š |
|
|
|
|
|
|
|
 |
Session 5 |
|
�À�@’· |
‘å–ì�@�@ŒM |
“Œ –k–ò‰È‘åŠw •a‘Ô�¶—�Šw‹³Žº |
|
|
|
5-1 |
IL-5ˆâ“`Žq“±“ü‚Í�DŽ_‹…‘�‘½‚ð—U“±‚µ�A‚»‚ÌŒã‚Ì�RŒ´“ÁˆÙ“I–Ɖu‰ž“š‚ð—}�§‚·‚é |
|
|
|
’†�ž�@ˆê”V |
“Œ‹ž‘åŠw ˆãŠw•” ƒAƒŒƒ‹ƒM�[�EƒŠƒEƒ}ƒ`“à‰È |
|
|
|
5-2 |
TAT-PTEN�×–E“à“±“ü‚É‚æ‚é�DŽ_‹…�¶‘¶‚Æ—V‘–‚Ì—}�§�@ |
|
|
|
‘«—§�@“N–ç |
’鋞‘åŠw ˆãŠw•” “à‰ÈŠw�u�À |
|
|
|
5-3 |
�DŽ_‹…�«è÷—±’`”’Major basic protein�iMBP�j‚ÍRespiratory syncytial virus�iRSV�j‚É‚æ‚é‹C“¹�ã”ç�×–E‚̃Aƒ|ƒg�[ƒVƒX‚¨‚æ‚Ñ‹C“¹‰Š�Ç‚ð‘�‹‚·‚é |
|
|
|
�Ήª�@‘å�¬ |
ŒQ”nŒ§‰q�¶ŠÂ‹«Œ¤‹†�Š |
|
|
|
|
|
|
|
|
5-4 |
ƒqƒg�D‰–Šî‹…‚ÌFas‚ð‰î‚µ‚½Apoptosis‚Ì—U“±‚ɂ‚¢‚Ä |
|
|
|
�¼–{�@Œ’Ž¡ |
�‘—§�¬ˆçˆã—ÃZƒ“ƒ^�[Œ¤‹†�Š –ƉuƒAƒŒƒ‹ƒM�[Œ¤‹†•” |
|
|
|
|
|
 |
Session 6 |
|
�À�@’· |
�Ö“¡�@”Ž‹v |
�‘—§�¬ˆçˆã—ÃZƒ“ƒ^�[Œ¤‹†�Š –ƉuƒAƒŒƒ‹ƒM�[Œ¤‹†•” |
|
|
|
6-1 |
�^‹Û�RŒ´‚É‚æ‚é‹C“¹�ã”ç�×–E‚ÌMUC5AC‚Ì”Œ» |
|
|
|
�¬ŒF�@�@�„ |
Œcœä‹`�m‘åŠw ˆãŠw•” ŒÄ‹zŠí“à‰È |
|
|
|
6-2 |
ƒqƒg‹CŠÇŽx•½ŠŠ‹Ø�×–E‚̕”|—{ƒRƒ‰�[ƒQƒ“ƒQƒ‹‚ð—p‚¢‚½Žû�kŽÀŒ±Œn‚ÌŠm—§ |
|
|
|
–k‘º�@‹IŽq |
�i“Æ�j�‘—§•a‰@‹@�\ ‘Š–ÍŒ´•a‰@ —Õ�°Œ¤‹†ƒZƒ“ƒ^�[ |
|
|
|
6-3 |
�¸�_“IƒXƒgƒŒƒX—U”�«šb‘§‚É‚¨‚¯‚é’†�•�_ŒoŒnƒÊ-ƒIƒsƒIƒCƒhŽó—e‘̂̊֗^‚ƖƉu‰ž“š�C�ü |
|
|
|
‰œŽR�@���D |
“Œ–k–ò‰È‘åŠw •a‘Ô�¶—�Šw‹³Žº |
|
|
|
|
|
 |
Session 7 |
|
�À�@’· |
“Œ“c�@—L’q |
‹ß‹E‘åŠwˆãŠw•”•�‘®•a‰@ ŒÄ‹zŠí�EƒAƒŒƒ‹ƒM�[“à‰È |
|
|
|
7-1 |
ƒXƒM‹}‘¬–Ɖu—Ö@‚É‚æ‚é�D‰–Šî‹…CD203c”Œ»•ω»‚ÌŒŸ“¢ |
|
|
|
’·”ö ‚݂Â٠|
�i“Æ�j�‘—§•a‰@‹@�\ ŽO�d•a‰@ —Õ�°Œ¤‹†•” |
|
|
|
7-2 |
ƒXƒMŒ¸Š´�ì—Ö@‚É‚¨‚¯‚錌�´’†blocking antibody‚ÉŠÖ‚·‚é‹@”\‰ð�Í |
|
|
|
�ì�ã�@ˆ»Žq |
“Œ‹ž‘åŠw ˆãŠw•” ƒAƒŒƒ‹ƒM�[�EƒŠƒEƒ}ƒ`“à‰È |
|
|
|
7-3 |
ƒXƒ^ƒ`ƒ“‚͔얞�×–E‚©‚ç‚̃TƒCƒgƒJƒCƒ“ŽY�¶‚ð—}�§‚·‚é |
|
|
|
‰Á�X”ü �Vˆê˜Y |
�ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ ˆâ“`Žq�§ŒäŠw |
|
|
|
|
|
 |
Session 8 |
|
�À�@’· |
�X�@�@�»•v |
�i“Æ�j�‘—§•a‰@‹@�\‘Š–ÍŒ´•a‰@
—Õ�°Œ¤‹†ƒZƒ“ƒ^�[ �æ’[‹Z�pŠJ”Œ¤‹†•” |
|
|
|
8-1 |
‹CŠÇŽxšb‘§Š³ŽÒ‚Ì––�½ŒŒ‚¨‚æ‚ьċC‹Ã�k‰t‚ð—p‚¢‚½Ž_‰»ƒXƒgƒŒƒX•]‰¿ |
|
|
|
—é–Ø �T‘¾˜Y |
�º˜a‘åŠw ˆãŠw•” ‘æˆê“à‰È |
|
|
|
8-2 |
Churg-Strauss syndrome�iCSS�j‚Ì•a‘ÔŒ`�¬‚Ö‚Ì�§Œä�«T�×–E‚ÌŠÖ—^‰¿ |
|
|
|
âV“¡�@”ŽŽm |
�i“Æ�j�‘—§•a‰@‹@�\ ‘Š–ÍŒ´•a‰@ —Õ�°Œ¤‹†ƒZƒ“ƒ^�[ |
|
|
|
8-3 |
�DŽ_‹…�«•›•@�o‰Š‚Ì—\Œã’²�¸�|Žè�pŒã5”N‚ÌŒo‰ßŠÏŽ@‚©‚ç�| |
|
|
|
�¼˜e�@—R“T |
“Œ‹žŽœŒb‰ïˆã‰È‘åŠw ˆãŠw•” ލ•@ˆô�A‰ÈŠw‹³Žº |
|
|
|
|
|
 |
Closing Remarks |
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |